search
Back to results

Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)

Primary Purpose

Fecal Incontinence

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Medical Device (SimplyFI)
Sponsored by
A.M.I. Agency for Medical Innovations GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fecal Incontinence focused on measuring Surgical Treatment, Implant

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Both male and female subjects Age ≥ 18 years, <85 years Subject has failed standard conservative therapy for fecal incontinence (at least 6 months) Subject is a surgical candidate Subject is willing and able to cooperate with follow-up examinations Subject has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes. Exclusion Criteria: Treatment with another investigational drug or investigational device Unable to understand study requirements or is unable to comply with follow-up schedule Contraindicated according to the instruction for use of the device Pregnancy or nursing, or plans to become pregnant History of significant obstructed defecation or other significant chronic defecatory motility disorders Current, external full thickness rectal prolapse or vaginal prolapse Inflammatory Bowel Disease Irritable Bowel Syndrome Systemic disease as source of FI (scleroderma, neurologic disorders, Crohn's) Active pelvic infection Chronic diarrhea Medical history of anal, rectal, or colon cancer Prior anterior resection of the rectum Medical history of pelvic radiation therapy Significant scarring of the recto-vaginal septum, a permanent implant in the rectovaginal septum, or a history of recto-vaginal fistula Previous anorectal posterior compartment surgery History of complex anal fistula

Sites / Locations

  • Göttlicher Heiland KrankenhausRecruiting
  • Medical University ViennaRecruiting
  • Klinikum Bielefeld RosenhöheRecruiting
  • MVZ Wiesbaden / KD Helios Klinik
  • Hospital Ruber InternacionalRecruiting
  • Hospital Universitario Ramón y CajalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Implantation of SimplyFI

Arm Description

Long-term non-active implant

Outcomes

Primary Outcome Measures

Safety-related complications and adverse events
The primary endpoint is safety-related complications and adverse events during follow-up until 12 months after surgery.

Secondary Outcome Measures

Cure of fecal incontinence (Fecal Incontinence Quality of Life Scale (FIQLs))
The secondary endpoint is to evaluate the change of fecal incontinence assessed by validated scores (changes from baseline to 1 week, 1 months, 3 months, 6 months) until 12 months after surgery. Fecal Incontinence Quality of Life scale (all subscale scores 1-4). Scales range from 1 to 5, with a 1 indicating a lower functional status of quality of life. Scale scores are the average (mean) response to all items in the scale.
Quality of Life (St. Mark's incontinence score (SMIS))
The secondary endpoint is to evaluate the change of Quality of Life assessed by validated scores (changes from baseline to 1 week, 1 months, 3 months, 6 months) until 12 months after surgery. St. Marks incontinence score contains 7 questions, and a higher total score means a worse outcome

Full Information

First Posted
January 23, 2023
Last Updated
September 12, 2023
Sponsor
A.M.I. Agency for Medical Innovations GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT05708612
Brief Title
Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)
Official Title
Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2023 (Actual)
Primary Completion Date
September 2025 (Anticipated)
Study Completion Date
September 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
A.M.I. Agency for Medical Innovations GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of the clinical investigation is to verify that the device under investigation (SimplyFI) is appropriate to significantly improve fecal incontinence in patients in whom its use is indicated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Incontinence
Keywords
Surgical Treatment, Implant

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
36 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Implantation of SimplyFI
Arm Type
Experimental
Arm Description
Long-term non-active implant
Intervention Type
Procedure
Intervention Name(s)
Medical Device (SimplyFI)
Intervention Description
Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.
Primary Outcome Measure Information:
Title
Safety-related complications and adverse events
Description
The primary endpoint is safety-related complications and adverse events during follow-up until 12 months after surgery.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Cure of fecal incontinence (Fecal Incontinence Quality of Life Scale (FIQLs))
Description
The secondary endpoint is to evaluate the change of fecal incontinence assessed by validated scores (changes from baseline to 1 week, 1 months, 3 months, 6 months) until 12 months after surgery. Fecal Incontinence Quality of Life scale (all subscale scores 1-4). Scales range from 1 to 5, with a 1 indicating a lower functional status of quality of life. Scale scores are the average (mean) response to all items in the scale.
Time Frame
12 months
Title
Quality of Life (St. Mark's incontinence score (SMIS))
Description
The secondary endpoint is to evaluate the change of Quality of Life assessed by validated scores (changes from baseline to 1 week, 1 months, 3 months, 6 months) until 12 months after surgery. St. Marks incontinence score contains 7 questions, and a higher total score means a worse outcome
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Both male and female subjects Age ≥ 18 years, <85 years Subject has failed standard conservative therapy for fecal incontinence (at least 6 months) Subject is a surgical candidate Subject is willing and able to cooperate with follow-up examinations Subject has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes. Exclusion Criteria: Treatment with another investigational drug or investigational device Unable to understand study requirements or is unable to comply with follow-up schedule Contraindicated according to the instruction for use of the device Pregnancy or nursing, or plans to become pregnant History of significant obstructed defecation or other significant chronic defecatory motility disorders Current, external full thickness rectal prolapse or vaginal prolapse Inflammatory Bowel Disease Irritable Bowel Syndrome Systemic disease as source of FI (scleroderma, neurologic disorders, Crohn's) Active pelvic infection Chronic diarrhea Medical history of anal, rectal, or colon cancer Prior anterior resection of the rectum Medical history of pelvic radiation therapy Significant scarring of the recto-vaginal septum, a permanent implant in the rectovaginal septum, or a history of recto-vaginal fistula Previous anorectal posterior compartment surgery History of complex anal fistula
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
A.M.I. Agency for Medical Innovations (Clinical Affairs)
Phone
+43 5522 90505-0
Email
ca@ami.at
First Name & Middle Initial & Last Name or Official Title & Degree
Florian Blab
Phone
+43 5522 90505-4062
Email
florian.blab@ami.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Riss, Prof. PD Dr.
Organizational Affiliation
Medical University Vienna
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
José Manuel Devesa Múgica, Dr.
Organizational Affiliation
Hospital Ruber Internacional
Official's Role
Principal Investigator
Facility Information:
Facility Name
Göttlicher Heiland Krankenhaus
City
Vienna
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michaela Lechner, Dr.in
First Name & Middle Initial & Last Name & Degree
Christian Kovats, Dr.
Facility Name
Medical University Vienna
City
Vienna
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Riss, Prof. PD Dr.
First Name & Middle Initial & Last Name & Degree
Christopher Dawoud, Dr.
Facility Name
Klinikum Bielefeld Rosenhöhe
City
Bielefeld
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mathias Löhnert, Prof. Dr.
First Name & Middle Initial & Last Name & Degree
Altankhuyag Ganjuur
Facility Name
MVZ Wiesbaden / KD Helios Klinik
City
Wiesbaden
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nils Habbe, Prof. Dr.
Facility Name
Hospital Ruber Internacional
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
José Manuel Devesa Múgica, Dr.
First Name & Middle Initial & Last Name & Degree
Rosana Vicente Prietro, Dra.
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Araceli Bellestro Pérez, Dra.
First Name & Middle Initial & Last Name & Degree
Javier Die Trill, Dr.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)

We'll reach out to this number within 24 hrs